How to Get Leqvio (Inclisiran) in Minnesota

What Leqvio Is and Where It Fits

Leqvio is the first FDA-approved small interfering RNA (siRNA) therapy for LDL cholesterol lowering. It works by reducing hepatic synthesis of PCSK9, a protein that normally limits how many LDL receptors the liver keeps on its cell surface. With less PCSK9 activity, the liver clears more LDL cholesterol from the blood. Its FDA-approved indication covers adults with heterozygous familial hypercholesterolemia (HeFH) or established ASCVD who need additional LDL-C reduction on top of maximally tolerated statin therapy.

It is not the same drug class as the monoclonal antibody PCSK9 inhibitors evolocumab (Repatha) or alirocumab (Praluent), which block circulating PCSK9 protein and require injections every two to four weeks. Inclisiran instead reduces PCSK9 production at the messenger-RNA level and is dosed twice yearly after two loading injections, which is the main practical difference patients and prescribers weigh.

The pivotal phase 3 trials for inclisiran (commonly referenced as ORION-10 and ORION-11) reported roughly 50 percent placebo-adjusted reductions in LDL-C sustained over the trial period, with a safety profile similar to placebo apart from injection-site reactions. Those specific trial identifiers and exact percentage figures should be confirmed against the current FDA label or the primary trial publications before being used in a clinical or payer document, since secondary summaries of these trials are not always accurate. More recent evidence has extended the drug's evaluated populations: a 2025 randomized trial examined inclisiran monotherapy in patients without established ASCVD (VICTORION-Mono), and a 2026 pooled analysis examined outcomes in patients with chronic kidney disease. Neither of these expands the FDA-approved indication on its own; they describe research populations that may not match a given patient's approved use. (VICTORION-Mono, 2025; CKD pooled analysis, 2026)

The 2025 American Association of Clinical Endocrinology (AACE) clinical practice guideline on pharmacologic management of dyslipidemia discusses PCSK9-targeted therapies, including inclisiran, as options for patients who remain above LDL-C goals on statin therapy. Specific numeric thresholds and step-therapy sequencing in that guideline should be checked against the full text before being quoted in a prior authorization letter, rather than relying on a paraphrase. (AACE 2025 guideline)

Who Qualifies

The FDA-approved indication is limited to two populations: adults with HeFH and adults with established ASCVD, used alongside maximally tolerated statin therapy when additional LDL-C lowering is needed. Diagnosis of HeFH is typically supported by genetic testing or validated clinical scoring systems (such as the Dutch Lipid Clinic Network criteria); ASCVD is typically documented through a history of myocardial infarction, ischemic stroke, peripheral arterial disease, or coronary revascularization recorded in the medical record.

Payers, including Minnesota commercial plans and Minnesota Medical Assistance (Medicaid), generally require documentation of an LDL-C value above a specific threshold while the patient is on a stable statin dose, plus evidence of a statin trial (and in some cases an ezetimibe trial) before approving inclisiran. The exact LDL-C cutoffs, required statin doses, and duration of prior trials differ by plan and change periodically. A prescriber preparing a prior authorization should pull the current criteria directly from the specific plan's published policy rather than relying on a generalized description, including this one.

Labs and Documentation Typically Requested

Before starting inclisiran, most Minnesota prescribers and payers expect:

• A fasting lipid panel with LDL-C measured while the patient is on a stable lipid-lowering regimen
• A comprehensive metabolic panel to establish baseline hepatic function, since the FDA label addresses inclisiran use in the context of hepatic impairment
• Baseline renal function (eGFR or serum creatinine), documented for record-keeping even though inclisiran does not require dose adjustment based on renal function according to available pharmacokinetic data
• Diagnosis-supporting documentation: a genetic test report or validated clinical score for HeFH, or medical records documenting an ASCVD event

Genetic testing is not uniformly required for ASCVD-based approvals but is commonly recommended for HeFH claims because it strengthens the diagnostic case for prior authorization. Specific payer-by-payer lab windows (for example, "labs must be drawn within 90 days") vary and should be confirmed with the plan at the time of submission rather than assumed from a generic figure.

Getting a Prescription in Minnesota: The Practical Path

1. Establish care with a Minnesota-licensed prescriber. A physician (MD or DO), a nurse practitioner with prescriptive authority, or a physician assistant with a valid supervising agreement can prescribe inclisiran if they hold an active Minnesota license. Cardiologists and lipid specialists prescribe it most often, but primary care clinicians may also do so. Telehealth visits with a Minnesota-licensed clinician are an accepted way to establish this relationship, provided the encounter meets the standard of care for history review, lab review, and documentation. Minnesota's prescriber licensing framework is administered by the Minnesota Board of Medical Practice. (mn.gov/boards/medical-practice)

2. Complete baseline labs. See the list above. Turnaround time depends on the specific lab and clinic.

3. Submit a prior authorization. This is the step most likely to cause delay. A complete submission generally needs the ICD-10 diagnosis code, a current LDL-C value with the date drawn, documentation of prior statin (and possibly ezetimibe) trials, and the prescriber's NPI. Minnesota Medical Assistance covers inclisiran with prior authorization for both HeFH and ASCVD indications; the DHS Pharmacy Prior Authorization unit handles these requests, and specific turnaround windows should be confirmed against current DHS policy rather than assumed. (mn.gov/dhs)

4. Specialty pharmacy dispensing. Leqvio is distributed through a manufacturer-linked specialty pharmacy network rather than a standard retail pharmacy, and it ships to the administering clinic rather than to the patient's home, because a healthcare professional must give the injection. Which specific specialty pharmacies serve a given plan in Minnesota depends on that plan's contracts and can change; confirm the current network with the prescribing office or the insurer.

5. In-clinic administration. The injection is given subcutaneously by a licensed clinical professional at Day 1, Day 90, and then roughly every 6 months per the approved dosing schedule. It is not self-administered.

If a prior authorization is denied, Minnesota law provides for an internal appeal, and if that fails, patients may request an external independent review through the Minnesota Department of Commerce. Specific appeal deadlines should be confirmed with the plan's denial letter and the Department of Commerce's current guidance. (mn.gov/commerce)

Telehealth Prescribing in Minnesota

Minnesota permits telehealth prescribing of inclisiran by clinicians who hold valid Minnesota prescriptive authority. The prescribing decision for this drug rests primarily on lab values and documented diagnosis rather than a physical exam finding, which is part of why a synchronous video visit can be clinically adequate for many patients. That said, the encounter still needs to meet Minnesota's standard-of-care requirements for establishing a valid patient-provider relationship, and those specific statutory and board requirements should be verified directly against current Minnesota Board of Medical Practice guidance rather than assumed from a summary.

Even after a telehealth prescription and prior authorization approval, the drug still ships to a clinical site, and the patient needs an in-person visit for each injection, roughly every 6 months after the loading doses. Patients relying on Minnesota Medical Assistance should also confirm that their telehealth provider is separately enrolled as a Minnesota Medical Assistance provider, since enrollment is required for Medicaid reimbursement regardless of telehealth modality.

Cost, Coverage, and Assistance Programs

Leqvio is a specialty biologic with a high list price, and affordability is a genuine access barrier for uninsured and underinsured patients. Manufacturer copay assistance and patient assistance programs are common for branded specialty drugs in this category, and Novartis has historically offered such programs for Leqvio. Because eligibility rules, dollar caps, income thresholds, and program terms for these programs change and typically exclude patients on federal insurance programs such as Medicare and Medicaid, do not rely on any specific number here. Confirm current program terms directly with the specialty pharmacy or Novartis at the time of prescribing, and note the date you verified it, since these terms are volatile.

Cost-effectiveness estimates for inclisiran exist in the published literature, but the figures vary substantially depending on assumptions about rebates, avoided cardiovascular events, and time horizon. A specific incremental cost-effectiveness ratio should not be treated as a fixed fact without checking the source study's assumptions and publication date.

503A Compounding: Why This Is Not a Workaround

Some patients ask whether a compounding pharmacy can prepare a lower-cost version of inclisiran. It cannot, in any way that carries the same evidence base. 503A pharmacies, including those licensed by the Minnesota Board of Pharmacy, compound drugs for individual patients under state and federal rules. (mn.gov/boards/pharmacy) FDA policy generally does not permit 503A pharmacies to compound copies of a commercially available, FDA-approved drug unless that drug appears on the FDA's drug shortage list. (FDA compounding Q&A) Inclisiran's shortage status can change; verify current status against the FDA's shortage database before relying on this as settled, and treat any claim about current shortage status as date-sensitive.

Separately, a compounded version of inclisiran, if one existed, would not carry the pharmacokinetic and clinical trial evidence base that supports the FDA-approved product's dosing and safety profile. Payers generally do not cover compounded versions of approved biologics, and the risk-benefit profile of any such compounded product would be undocumented.

Realistic Timeline

Getting from first consultation to first injection in Minnesota typically involves: an initial visit with lab orders, lab turnaround, prior authorization submission and decision, specialty pharmacy processing and shipping to the clinic, and scheduling the injection visit. Each of these steps has a real range that depends on the specific payer, lab, and pharmacy involved, and those ranges shift over time. Rather than quote a single week count as fixed, treat the total timeline as multi-week under normal conditions and expect it to lengthen meaningfully if the prior authorization is denied and an appeal is needed. Patients with existing labs on file and an established prescriber relationship can generally move faster than patients starting from a first visit.

Transferring Care to Minnesota

Patients relocating to Minnesota who already receive inclisiran can generally continue therapy by having their existing specialty pharmacy network arrange dispensing to a new Minnesota administering clinic. Whether a new prior authorization is required generally depends on whether the patient's insurance changes with the move; a plan change almost always triggers a new prior authorization under the new plan's criteria. Bringing documentation of prior injection dates, the most recent LDL-C result, and the original approval letter to the new Minnesota prescriber helps avoid re-doing diagnostic workup. Patients moving from Veterans Affairs care to civilian care should expect that VA formulary and mail-order logistics differ from civilian specialty pharmacy processes, and should request a written transition-of-care summary from their VA provider.

Monitoring After Starting

A fasting lipid panel around 90 days after the first injection lets the prescriber assess response before the second loading dose, and lipid panels roughly every 6 months thereafter, timed to maintenance injections, are the standard monitoring pattern described in labeling. Liver function testing is not required on a fixed routine schedule by the FDA label for patients without pre-existing hepatic disease, though many clinicians check it opportunistically at visits already scheduled for other reasons. A patient who does not show a meaningful LDL-C drop by the 90-day check warrants a review of adherence, concurrent medication changes, and whether the diagnosis and dosing were correctly documented, rather than an assumption that the drug has failed.

Large cardiovascular outcomes data for inclisiran (whether LDL-C lowering with this drug translates into fewer heart attacks and strokes at a population level) is an area of ongoing research. Readers should treat "confirmed to reduce cardiovascular events" as a stronger claim than the currently available evidence for inclisiran itself supports, distinct from the class-level outcomes evidence that exists for other LDL-lowering therapies such as statins and monoclonal PCSK9 inhibitors.

Verification Checklist: What's Settled vs What You Must Confirm Yourself

Some facts about inclisiran access in Minnesota are stable and unlikely to change quickly. Others are tied to a specific insurer, pharmacy, or point in time and must be re-checked before you act on them. Use this checklist to separate the two before submitting a prior authorization or counseling a patient on cost.

Stable, federal or clinical facts (safe to rely on without re-verification in the near term):

• Inclisiran's FDA-approved indications are HeFH and established ASCVD, as an adjunct to statin therapy
• The approved dosing pattern is Day 1, Day 90, then roughly every 6 months, administered by a healthcare professional
• Inclisiran works by reducing hepatic PCSK9 synthesis, distinct from the monoclonal antibody PCSK9 inhibitors
• Minnesota licensing law allows MDs, DOs, NPs with prescriptive authority, and PA-Cs to prescribe specialty lipid-lowering drugs, including via telehealth, when licensing and standard-of-care requirements are met

Date-sensitive facts you must re-verify before relying on them (check the date you verified each one):

• Whether inclisiran currently appears on the FDA drug shortage list, which affects whether compounding is even a live question
• The specific LDL-C threshold, statin dose, and ezetimibe trial duration your patient's exact plan requires for prior authorization approval
• Which specialty pharmacies are in-network for a given Minnesota payer
• Current prior authorization processing timelines for the specific commercial plan or for Minnesota Medical Assistance
• Current list price, copay assistance program terms, and patient assistance foundation eligibility rules
• Whether a given telehealth provider is separately enrolled as a Minnesota Medical Assistance provider, if the patient is on Medicaid

When reviewing inclisiran data in the second list, verify any item against a recent source before citing it; do not rely on previously encountered figures without confirmation of their currency.

Evidence Boundary

Established: inclisiran's FDA-approved indications, its general mechanism, its twice-yearly dosing pattern after loading doses, and the requirement that it be administered by a healthcare professional. Established: that prior authorization is the near-universal access gate for this drug across Minnesota payers, including Medicaid.

Plausible but not settled here: exact percentage LDL-C reductions, specific p-values, and named trial identifiers attributed to this drug's pivotal studies, which appear in secondary sources with varying accuracy and should be confirmed against the primary trial publications or the current FDA label before being used in patient-facing or payer-facing documents. Cardiovascular outcomes (event reduction, not just LDL-C lowering) for inclisiran specifically remain an area of ongoing research rather than a settled finding.

Not established from the material available for this page: any specific dollar figure for list price, copay assistance amount, or cost-effectiveness ratio; any specific number of days for prior authorization processing by a named Minnesota payer; and any claim that a Minnesota 503A pharmacy is currently compounding inclisiran.